Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs.
Treatment of pain in rheumatoid arthritis must take into account the gastrointestinal and cardiovascular risk of individual patients. Adequate results are not yet available, and until they are, treatment recommendations must take into account, not only the more favourable gastrointestinal risk profile of selective COX-2 inhibitors, but also the potential atherothrombotic risk of any NSAID or selective COX-2 inhibitor treatment.
Bolten
W W
WW
wbolten@em.uni-frankfurt.de
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D050197:Atherosclerosis / Q000139:chemically induced*; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects; D006801:Humans; D013927:Thrombosis / Q000139:chemically induced*; D013928:Thromboxane A2 / Q000378:metabolism
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D013928:Thromboxane A2